Published in Clinics (Sao Paulo) on January 01, 2013
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med (2012) 10.07
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood (2008) 7.73
Myelofibrosis with myeloid metaplasia. N Engl J Med (2000) 7.04
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia (2010) 4.09
Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol (2011) 4.06
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood (1996) 3.13
Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia (2008) 3.04
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis. Blood (2007) 2.41
Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med (2011) 1.96
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood (2005) 1.92
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood (2009) 1.78
Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res (2012) 1.35
U.S. Food and Drug Administration approval: ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res (2012) 1.31
Genetics of the myeloproliferative neoplasms. Curr Opin Hematol (2011) 1.08
Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. Blood (2011) 1.04
Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms. Curr Opin Oncol (2011) 0.94
Ruxolitinib for myelofibrosis. N Engl J Med (2012) 0.85
Advances in the understanding and management of primary myelofibrosis. Curr Opin Oncol (2011) 0.84
Prognostication in primary myelofibrosis. Curr Hematol Malig Rep (2012) 0.81
Identification of target genes using gene expression profile of granulocytes from patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma (2014) 1.42
Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma. PLoS One (2011) 1.22
Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project - 2012. Rev Bras Hematol Hemoter (2012) 1.22
Pancytopenia in untreated patients with Graves' disease. Thyroid (2006) 1.14
Serum cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell transplantation. Exp Hematol (2003) 1.13
A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia. Crit Care (2013) 1.12
The impact of maternal HIV infection on cord blood lymphocyte subsets and cytokine profile in exposed non-infected newborns. BMC Infect Dis (2011) 1.05
The fractal dimension of nuclear chromatin as a prognostic factor in acute precursor B lymphoblastic leukemia. Cell Oncol (2006) 0.99
Causes of incidental neutropenia in adulthood. Ann Hematol (2006) 0.95
Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes. Leuk Res (2005) 0.93
High expression of FMNL1 protein in T non-Hodgkin's lymphomas. Leuk Res (2006) 0.93
Leptin inhibits apoptosis in thymus through a janus kinase-2-independent, insulin receptor substrate-1/phosphatidylinositol-3 kinase-dependent pathway. Endocrinology (2006) 0.93
An algorithm based on peripheral CD34+ cells and hemoglobin concentration provides a better optimization of apheresis than the application of a fixed CD34 threshold. Transfusion (2008) 0.92
Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS One (2013) 0.91
Phenotypic subtypes of acute lymphoblastic leukemia associated with different nuclear chromatin texture. Anal Quant Cytol Histol (2008) 0.90
Imbalances in serum angiopoietin concentrations are early predictors of septic shock development in patients with post chemotherapy febrile neutropenia. BMC Infect Dis (2010) 0.90
Adrenocortical tumors in Brazilian children: immunohistochemical markers and prognostic factors. Arch Pathol Lab Med (2005) 0.88
Time-course of sFlt-1 and VEGF-A release in neutropenic patients with sepsis and septic shock: a prospective study. J Transl Med (2011) 0.88
Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Acta Haematol (2005) 0.87
Quantifying loss of CD34+ cells collected by apheresis after processing for freezing and post-thaw. Transfus Apher Sci (2013) 0.86
Relationship between cytokine gene polymorphisms and graft-versus-host disease after allogeneic stem cell transplantation in a Brazilian population. Cytokine (2005) 0.86
Philadelphia-negative chronic myeloproliferative neoplasms. Rev Bras Hematol Hemoter (2012) 0.86
Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol (2012) 0.86
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort. Acta Haematol (2013) 0.85
Goodness-of-fit of the fractal dimension as a prognostic factor. Cell Oncol (2009) 0.84
Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes. Eur J Haematol (2014) 0.83
Infection of Calomys callosus (Rodentia Cricetidae) with strains of different Trypanosoma cruzi biodemes: pathogenicity, histotropism, and fibrosis induction. Mem Inst Oswaldo Cruz (2004) 0.83
Participation of leptin in the determination of the macrophage phenotype: an additional role in adipocyte and macrophage crosstalk. In Vitro Cell Dev Biol Anim (2013) 0.82
Orbital lymphoma mimicking ophthalmopathy in a patient with Graves'. Am J Med Sci (2012) 0.82
Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma (2010) 0.82
Associations of VEGF and VEGFR2 polymorphisms with increased risk and aggressiveness of multiple myeloma. Ann Hematol (2014) 0.82
Molecular characteristics and chromatin texture features in acute promyelocytic leukemia. Diagn Pathol (2012) 0.82
[Association between HLA and leukemia in a mixed Brazilian population]. Rev Assoc Med Bras (2007) 0.82
Flow cytometric analysis of the expression of Fas/Fasl in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression. Leuk Lymphoma (2004) 0.81
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res (2007) 0.81
GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol (2007) 0.80
Lipopolysaccharide treatment reduces rat platelet aggregation independent of intracellular reactive-oxygen species generation. Platelets (2011) 0.80
Alterations in cell maturity and serum survival factors may modulate neutrophil numbers in sickle cell disease. Exp Biol Med (Maywood) (2011) 0.79
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes. Clinics (Sao Paulo) (2011) 0.79
The rare t(6;8) (q27;p11) translocation in a case of chronic myeloid neoplasm mimicking polycythemia vera. Leuk Lymphoma (2008) 0.79
Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation. Virchows Arch (2013) 0.79
Glial fibrillary acidic protein in tumor types with cartilaginous differentiation. Mod Pathol (2009) 0.79
Polymorphisms of VEGF, GSTM1 and GSTT1 genes in multiple myeloma risk. Hematol Oncol (2011) 0.78
Molecular identification of the HLA-DRB1-DQB1 for diagnosis and follow-up of acute leukemias. Blood Cells Mol Dis (2010) 0.78
Downregulation of IRS2 in myelodysplastic syndrome: a possible role in impaired hematopoietic cell differentiation. Leuk Res (2012) 0.78
Brazilian experience using high-dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for relapsed or refractory Hodgkin lymphoma. Clin Lymphoma Myeloma (2009) 0.78
Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene. Am J Clin Pathol (2008) 0.78
Cytomegalovirus frequency in neonatal intrahepatic cholestasis determined by serology, histology, immunohistochemistry and PCR. World J Gastroenterol (2009) 0.78
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response. Rev Bras Hematol Hemoter (2011) 0.78
Further remarks on the expression of CD20 in classical Hodgkin's lymphomas. Haematologica (2002) 0.78
Viability of umbilical cord blood mononuclear cell subsets until 96 hours after collection. Transfusion (2013) 0.77
The Brazilian Pediatric Myelodysplastic Cooperative Group strategies: are they relevant to improve educational approach and correct diagnosis? Leuk Res (2002) 0.77
Treatment outcome of acute promyelocytic leukemia with modified aida protocol. Adv Hematol (2010) 0.77
Mutations in the p53 gene in acute myeloid leukemia patients correlate with poor prognosis. Hematology (2002) 0.77
Spontaneous apoptosis in chronic lymphocytic leukemia is not an independent prognostic factor for stability of disease when compared with combined AgNOR and TTM scores. Cell Oncol (2005) 0.77
The influence of the graft monocytes in the outcome of allogeneic bone marrow transplantation. Haematologica (2002) 0.77
Circulating progenitor and mature endothelial cells in deep vein thrombosis. Int J Med Sci (2013) 0.77
Reduced expression of FLIP SHORT in bone marrow of low risk myelodysplastic syndrome. Leuk Res (2007) 0.76
Polymorphisms of glutathione S-transferase Mu 1, glutathione S-transferase theta 1 and glutathione S-transferase Pi 1 genes in Hodgkin's lymphoma susceptibility and progression. Leuk Lymphoma (2009) 0.76
Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma. PLoS One (2013) 0.75
Brazilian experience using high dose sequential chemotherapy followed by autologous hematopoietic stem cell transplantation for malignant lymphomas. Rev Bras Hematol Hemoter (2011) 0.75
No contribution of GSTM1 and GSTT1 null genotypes to the risk of neutropenia due to benzene exposure in Southeastern Brazil. Genet Mol Biol (2009) 0.75
Aluminum concentrations in central and peripheral areas of malignant breast lesions do not differ from those in normal breast tissues. BMC Cancer (2013) 0.75
Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis (2012) 0.75
HER2 expression in Brazilian patients with estrogen and progesterone receptor-negative breast carcinoma. Acta Histochem (2012) 0.75
CMV-DNA detection in patients with thrombocytopenia. Sao Paulo Med J (2002) 0.75
Dural lymphoma mimicking subdural haematoma on computerized tomography. Br J Haematol (2015) 0.75
Prostatic atrophy: immunohistochemical study of hypoxia induced factors. Int Urol Nephrol (2006) 0.75
Bone marrow lymphoid aggregates in myelodysplastic syndromes: incidence, immunomorphological characteristics and correlation with clinical features and survival. Leuk Res (2002) 0.75
p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol (2006) 0.75
Changes in hemopoietic precursors after treatment of low-risk myelodysplasia with amifostine. In Vivo (2003) 0.75
The influence of storage and leukocyte depletion on the antigen densities of FY1, FY2, MNS3 and MNS4 measured by flow cytometry. Transfus Apher Sci (2008) 0.75
Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast. Int J Biol Markers (2010) 0.75
Primary meningeal melanocytoma mimicking a nonfunctioning pituitary adenoma. Clin Neuropathol (2016) 0.75
Acquired thrombotic thrombocytopenic purpura due to antibody-mediated ADAMTS13 deficiency precipitated by a localized Castleman's disease: a case report. Platelets (2014) 0.75
The prognostic relevance of apoptosis-related proteins in classical Hodgkin's lymphomas. Leuk Lymphoma (2003) 0.75
Expressions of the VLA-4, LFA-1 and Mac-1 integrins in eosinophil migration in a case of chronic eosinophilic leukaemia. Leuk Res (2006) 0.75
Mechanisms underlying the inhibitory effects of lipopolysaccharide on human platelet adhesion. Platelets (2010) 0.75